News

The approval has been granted to treat patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test whose disease has progressed on or after an

The 11 successful projects were selected through a competitive process from 168 applications from around the world. The awarded grants were based on the merits of each of

Agenus plans to close its Basel site and consolidate key functions to its Cambridge, UK and Lexington, MA facilities, and phase out approximately 50 positions across the organization.

The study’s primary objective was to test safety and tolerability of anabasum in adults with CF who had FEV1 ≥ 40% predicted and remained on background CF medications,

Results from the 377-subject trial show a clinically meaningful benefit to subjects in the reduction of lactose intolerance symptoms across a variety of outcome measures. The majority of

The collaboration combines Warp Drive’s Small Molecule-Assisted Receptor Targeting (SMART™) platform with GSK’s expertise in Encoded Library Technology (ELT) to discover drugs that address high-value intractable targets. “This

Ocrevus is a humanised monoclonal antibody that can selectively target CD20-positive B cells, a specific type of immune cell tha is expected to cause myelin (nerve cell insulation

The agency also granted priority review status with a Prescription Drug User Fee Act (PDUFA) set for third quarter of this year. Lynparza tablets are an investigational formulation and are

Zejula is a poly(ADP-ribose) polymerase (PARP) inhibitor which has to be taken orally daily once. It has been approved for the maintenance treatment of adult patients with recurrent epithelial